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Slllnnlal'y 
CD4 is the primary receptor for the human irnmunodeficiency  virus type 1 (HIV-1). Early mutational 
studies implicated a number of residues of CD4,  centered in the region  41-59,  in binding  to 
gpl20. However, further mutational analyses, together with studies using inhibitory antibodies 
or CD4-derived peptides, have suggested that other regions of CD4 are also involved in binding 
or postbinding events during infection. To resolve these ambiguities, we used rat CD4 mutants 
in which particular regions were replaced with the corresponding sequence of human CD4. We 
have previously shown that some of these are able to bind HIV-1 gpl20, and here we test their 
ability to act as functional receptors.  We find that the presence of human CD4 residues 33-62 
is enough to confer efficient receptor function to rat CD4,  and we conclude that it is unlikely 
that regions of CD4 outside this sequence are involved in specific interactions with HIV-1 during 
either  infection or syncytium formation. 
T 
he CD4 cell surface glycoprotein is the primary receptor 
for HIV-1, and its high affinity interaction with the viral 
glycoprotein gp120 is the initial  step in HIV-1 infection of 
most susceptible cells (1, 2). The extracellular region of CD4 
contains four Ig superfamily domains,  the amino  terminal 
of which closely resembles an Ig light chain variable domain 
(3, 4). The three-dimensional structure of the amino-terminal 
two domains  has  been confirmed by x-ray crystallography 
(5, 6).  In vitro mutational  analyses  have identified residues 
41-59 within the C'-C" ridge of CD4 domain 1 as the prob- 
able binding  site for gpl20  (5,  7-11). 
The postbinding  events that  lead to fusion of the virus 
and cellular membranes are unclear.  CD4 may induce con- 
formational changes in gpl20 that expose the fusogenic re- 
gion of gp41 (12-15).  It has been proposed that regions of 
CD4 outside the gp120-binding  site might  be involved in 
this process (16-18). For example, mAbs that bind the F-G 
turn (equivalent to the CDR3 loop of Igs) block syncytium 
formation and viral entry while only poorly inhibiting  the 
binding of gpl20 or HIV-1 (16). Derivatized peptides corre- 
sponding to residues 81-92 of human (h) 1 CD4, which en- 
compass this loop, inhibit postbinding events (17). Another 
study implicated this region by demonstrating that chimpanzee 
1  Abbreviations  used in this  paper: h, human; m, mutant; m.o.i., multiplicity 
of infection; r, rat. 
CD4 and hCD4 with a chimpanzee CDR3 loop were un- 
able to mediate HIV-l-dependent syncytium formation, un- 
like wild-type hCD4 or chimpanzee  CD4 with a hCDR3 
loop (19). 
Rat (r)CD4 shares only 50% homology with hCD4 and 
does not  function  as a receptor for HIV-1.  We have taken 
advantage of this to determine the regions of CD4 involved 
in  HIV-1  infection  by replacing  rCD4  sequence with  the 
equivalent hCD4 residues.  Using this approach initial studies 
established that  the gp120 binding  site of CD4 is encom- 
passed by residues 33-62 of domain  1 (20).  In the present 
study we have taken the analysis  a stage further and deter- 
mined whether regions outside the gp120 binding site of CD4 
are involved in the postbinding events of viral entry and syn- 
cytium formation. The results show that a mutant form of 
rCD4 containing residues 33-62 of hCD4 is an efficient medi- 
ator of HIV-1 infection and syncytium formation. This sug- 
gests that regions outside residues 33-62 are unlikely to be 
involved in  these postbinding  events. 
Materials  and Methods 
CelILines.  The human carcinoma cell line, HeLa (21), the mouse 
fibroblast cell line, L929 (22), and the baby hamster kidney cell 
line, BHK-21 (23), were obtained  from Flow Laboratories, Inc. 
(McLean, VA). H32 cells, HeLa cells expressing HIV-1 Env, were 
obtained from Dr. Lee Bacheler (DuPont Co., Wilmington, DE). 
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FCS (Gibco-BRL, Gaithersburg, MD), 2 mM t-glutamine (Sigma 
Chemical Co., St. Louis, MO), and antibiotics (50 U/ml penicillin, 
50 #g/ml streptomycin, and 100 #g/ml neomycin). In addition, 
H32 cells were maintained in 0.6 mg/ml G418 (Sigma Chemical 
Co.). The human T lymphotropic virus type 1-transformed T cell 
line, C8166 (24), and the T lymphoblastoid cell line, H9 (25), were 
obtained from the National Institutes of Health AIDS Research 
Reagent Program. These cell lines were maintained in KPMI 1640 
with  10%  FCS,  t-glutamine, and antibiotics. 
Generation of HeLa Cell Lines Expressing CD4.  The cDNAs of 
CD4, rCD4, and mutant (m)2 and m6 were subcloned into the 
pKG5 vector (26). HeLa cells were stably transfected using the cal- 
cium phosphate precipitation method, as described (27). Cells ex- 
pressing the different constructs were selected and maintained in 
DME complete medium containing 0.6 mg/ml G418 (Sigma Chem- 
ical Co.). The transfected cells were analyzed and sorted by FACS  | 
(Becton Dickinson & Co., Mountain View, CA). RF-T4 mAb (28) 
(MRC  AIDS-Directed  Programme)  and  MRC-OX-71  mAb 
(directed against domains 3 and 4 of rCD4;  A. N. Barclay, per- 
sonal communication) were used to determine the levels of h- and 
rCD4, respectively.  MRC-OX-21 mAb (anti-human C3b inacti- 
vator, c3bINA) was used as a negative control, and MR.C-W6/32 
mAb (anti-human MHC-I) as a positive control. FITC-conjugated 
rabbit anti-mouse Ig (KAM-FITC) (Serotec Ltd., Oxford, UK) 
was  used as the second antibody. 
Viruses.  HIV-lmB (29) was obtained from the NIH AIDS Re- 
search and Reference Reagent Program and propagated by acute 
infection of C8166 cells. The culture supernatants were clarified, 
filtered through 0.45-#m filters,  treated with 40 U/m1 DNase I 
(Sigma Chemical Co.) for 30 min at room temperature to remove 
detectable proviral DNA, and stored in 1-ml aliquots at  -80~ 
Cocal Virus (COC) (30) was obtained from Robert Shope (Yale 
Arbovirus Unit,  New Haven, CT). BHK-21 cells were infected 
with COC at a multiplicity of infection (m.o.i.) of 10 -s and, after 
24 h, cell supernatants were harvested, darified, and stored at -80~ 
in  1-ml aliquots. 
Titration  of Viruses.  HIV-lulB infectivity was  determined  as 
follows.  10~  dilutions  of virus  were  incubated  with 
0.1 ml of C8166  cells (5  x  10  s cells/m1; eight replicates  per 
dilution) for 4 d at 37~  or with 5  x  103 HeLa CD4 cells for 
8 d. The cells were lysed and proviral DNA amplified by PCK using 
LTK-specific primers (31). The mean number of infectious units 
per sample was determined from the frequency of null samples at 
a given dilution using the Poisson distribution. COC was titrated 
by plaque assay on BHK-21 cells (32). 
Measurement of Virus Production.  Mutant and wild-type CD4- 
expressing HeLa cells were challenged with HIV-lmB at an m.o.i. 
of 2  x  10 -4 (virus titrated on HeLa cells expressing  hCD4) and 
grown in culture for 1 mo. The ceils were split and counted every 
3 d and samples of culture supernatant were taken for analysis by 
p24 ELISA and reverse transcriptase assay (33). Standard methods 
were used for p24 ELISA (34). Capture antibody was affinity-purified 
sheep anti-HIV-l-p24 Gag polyclonal antibody (1 #g/well; Aalto 
Bioreagents, Dublin, Ireland). Detection antibody was EH12-E1 
(35) biotinylated using D-biotinoyl-e-aminocaproic acid-N-hydroxy- 
succinimide ester (Boehringer Mannheim Biochemicals,  Indianap- 
olis,  IN). 
Detection of Viral Entry Into Cells by the PCR.  HeLa ceils ex- 
pressing rCD4, m2, m6 or hCD4 were challenged  with HIV-lmB 
(m.o.i.  of 10-2;  virus titrated in HeLa hCD4)  for 2 h,  washed 
twice in PBS, and incubated at 37~  for a further 18 h. Lysates 
were prepared and PCK amplifications performed as described rise- 
where (31). The lysates were serially diluted, using uninfected HeLa 
cell lysates as the diluent, and HIV-1 provirus was amplified by PCR 
to produce a semiquantitative measure of viral entry. The primers 
used to detect HIV-1 proviral DNA amplified a 540-bp fragment 
of the LTR. To check that equal numbers of cells from each cell 
line were used, the lysates were serially diluted using mouse L929 
cell lysate as the diluent, and analyzed by PCK using primers to 
a 238-bp region of human/~-globin  gene (for primer sequences 
see reference 31). 
Pseudotype Assays.  H9 cells were infected with HIV-lnIB at an 
m.o.i, of 10 -2 and incubated for 10 d. The cells were then superin- 
fected with COC at an m.o.i, of 10-4 and incubated for a further 
24 h. Infected cell supernatants were then harvested,  clarified by 
centrifugation, and stored at  -80~  Virus was preincubated for 
30 min at room temperature with either rabbit anti-COC serum 
(1:100  dilution,  having  the  potency  to  neutralize  >106 COC 
PFU/ml)  to detect COC(HIV)  pseudotypes;  rabbit  anti-COC 
serum  and sheep  anti-HIV-1  gp120  (MRC  AIDS-Directed Pro- 
gramme reference ADP401 used at 1:80 dilution) to detect back- 
ground PFUs; or with growth medium to titrate total COC PFUs. 
The preincubated samples were then used in plaque  assays with 
the cells of interest (32). 
Syncytium Assays.  Trypsinized H32 cells were mixed with an 
equal number of CD4-expressing HeLa cells, and placed in sterile 
petri dishes containing a cover slip. After overnight incubation at 
370C, the cells were fixed for 5 min in methanol and stained for 
10 min in phosphate buffer, pH 6.8, containing 10% Giemsa's stain 
and 1% May and Grunwald's stain (BDH Chemicals Ltd., Poole, 
Dorset, UK). The coverslips were mounted on slides and the number 
and size of syncytia counted. 
Results 
m2 and m6 consist of rCD4 in which residues 36-62 and 
33-62, respectively, of domain 1 have been replaced with the 
corresponding sequence of hCD4 (20). The affinities of m2 
and m6 for gp120 are 70- and 2-fold lower, respectively, than 
that  of hCD4  (20).  HeLa cells were transfected with con- 
structs encoding these two mutants and those encoding h- and 
rCD4.  After up to two rounds  of sorting of HeLa rCD4, 
HeLa m2,  and HeLa m6,  the level of surface expression of 
CD4  was  essentially the same  (Fig.  1) for each cell line. 
HIV-I Replication.  The cells were challenged with HIV-1 
and samples were collected every 3 d for 1 mo postinfection 
for  analysis  by p24  ELISA  and  reverse transcriptase  assay. 
Similar levels of HIV-1 replication were detected in HeLa hCD4 
and HeLa m6, although the kinetics were delayed by 2-3 d 
in the latter (Fig. 2). In contrast, no p24 or reverse transcrip- 
tase were detected in the cell culture supernatants  of either 
HeLa rCD4  or HeLa m2  even  1  mo  after challenge.  The 
growth rate of each cell line was found to be the same (results 
not shown). During the course of infection cytopathic effects 
and syncytia were observed first in the culture of HeLa hCD4 
cells and a few days later for HeLa m6 cells, but were not 
seen in either HeLa rCD4 or HeLa m2 cultures. The results 
show that m6 is an efficient receptor for HIV-1 whereas m2 
is not. 
Syncytium  Assay.  To determine whether  the differences 
in ability of each mutant to support HIV-1 propagation in 
culture were mainly det~a~ined by the ability of virus to spread 
by cell-cell fusion, we tested the ability of each molecule to 
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Figure  1.  Measurement of mutant and wild-type CD4 expression in 
transfected HeLa cells by indirect flow cytometry. The levels of CD4 ex- 
pression were measured by FACS  |  analysis. Cells were labeled first with 
mouse mAbs and then with RAM-FITC. The first mAbs were: OX-21 
(C3bINA), negative  control; W6/32 (anti-human MHC-I), positive  con- 
trol; OX-71 (anti-rat CD4) or R.F-T4 (anti-human CD4). 
support HIV-1 Env-dependent syncytium formation in a virus- 
free system. HeLa cells expressing the HIV-1 Env were mixed 
with each CD4-expressing  cell line and  these were scored 
for frequency and size of syncytia. Fig. 3 shows that rCD4 
is unable to support the formation of syncytia. Both HeLa 
hCD4 and HeLa m6 produced a high level of syncytia, the 
size and frequency of which could not be distinguished,  and 
m2 supports a low but significant level of syncytium formation. 
Viral Entry.  Since m6 and hCD4 have indistinguishable 
syncytium-inducing ability, inefScient cell-cell spread of HIV-1 
cannot account for the slight delay in replication kinetics ob- 
served in HeLa m6 cells.  One possibility is that it may be 
due to a lower e~ciency of infection by cell-free virions since 
the affinities of m2 and m6 for gp120 are •70-  and 2-fold, 
respectively, lower than that of wild-type CD4 (20). To test 
this,  we used three independent  measures of viral entry. 
Semiquantitative PCR was used with LTP,-specific primers 
to measure the amount of provirus formed during the first 
round of infection.  CD4-expressing  HeLa cells were chal- 
lenged with HIV-1 and lysed after 20 h, before a second round 
of infection could take place. The lysates were serially diluted 
(10~  dilutions),  and proviral DNA  was  amplified by 
PCR (see Fig. 4 A). The results show that entry and reverse 
transcription were "~10-fold less efficient in HeLa m6 than 
in HeLa hCD4.  In comparison, entry and reverse transcrip- 
tion was ,v300-fold less efficient in HeLa m2 than in HeLa 
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Figure 2.  Production  of  HIV-1  by mutant and wild-type  CD4-expressing 
HeLa cells. HeLa rCD4 (O), HeLa m2 (~7), HeLa m6 (O), and HeLa 
hCD4 (V) were challenged  with HIV-1, and samples of cell culture super- 
natant were taken every 3 d postinfection and analyzed for the presence 
of HIV-1 by (A) ELISA and (8) reverse  transcriptase assay. The lower de- 
tection limit for each assay was ",0.1 ng/ml and ,~103 cpm/ml, respec- 
tively. 
100  ....  , 
10 
Cq 
O 
0.1  111 
2  3-5  6-8  9-11  >11 
No. nuclei per cell 
Figure 3.  Syncytium-forming  ability of HeLa cells expressing mutant 
and wild-type CD4. HeLa rCD4 (open columns), HeLa m2 (light-shaded 
columns), HeLa m6 (medium-s~ded  columns), and HeLa hCD4 (dark-shaded 
columns)  were mixed with HeLa cells expressing  HIV-1 envelope  glycopro- 
teins and the cultures were scored for the frequency and size of syncytia 
after overnight cocultivation. For each cell line and coculture, 10 fields 
of view containing at least 200 cells were scored. The columns show the 
average (+_ SD) percentage of cells in the population containing one or 
a specified number of nuclei. No cells containing more than five nuclei 
were  detected in any unmixed cultures. 
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HeLa cells, and this may reflect the previously described ineffi- 
cient CD4-independent entry of HIV-1 into HeLa cells (36). 
Finally,  a stock of HIV-lmB with an infectivity of '~107 
C8166-infectious  U/ml was titrated on HeLa m6 and HeLa 
hCD4 cells. The titer of this stock was 2.2  _+  1 and 6.9  _+ 
3  x  103  infectious U/ml  in HeLa m6  and HeLa hCD4, 
respectively.  Since an infectivity assay of this sort is only a 
reliable measure of entry if a single infection event produces 
sufficient progeny virus to be measured, the infectivity for 
HeLa rCD4  and  HeLa m2  were  not investigated by this 
method. 
Figure  4.  Infectability  of HeLa  cells expressing mutant and wild-type 
CD4 by HIV-1. (A) Semiquantitative  PCR assay  of first-round  provirus 
formation. Mutant and wild-type  CD4-expressing HeLa  cells were chal- 
lenged with HIV-1 at an m.o.i, of 0.01. The cells were lysed 20 h post 
infection  and then serially  diluted  in uninfected  L929 cell lysate  (10o.S-fold 
series). PCR was used to amplify  a 540-bp fragment  of the HIV LTIL. 
(Lane 1) HeLa  rCD4, 100 dilution; (lanes 2-6) HeLa  m2, 10~  -2 dilu- 
tions; (lanes 7-15) HeLa m6, 10O-10  -3.s dilutions; (lanes 16-23) HeLa 
hCD4, 10~  - 3.s dilutions.  Semiquantitative  PCR of the HeLa  CD4 ly- 
sates using  globin-specific  primers  confirmed  that there  were  equal  numbers 
of cells in each of the lysates  (results not shown). The position of molec- 
ular weight  markers is shown (lane  24). (B) Pseudotype  assay. Untrans- 
fected and CD4-expressing cells were challenged  with COC(HIV) pseu- 
dotypes.  Unshaded  columns  show  the titer  of  COC in each  cell  line. Shaded 
columns show the titer of pseudotype (HIV-I-dependent entry). 
hCD4. As expected there was no HIV-1 entry into HeLa rCD4 
cells (Fig.  4 a). 
Viral entry was also studied using COC(HIV) pseudotype 
assays. The pseudotypes have the genome of COC, a plaque~ 
forming virus, and the envelope glycoprotein of HIV-1, thereby 
enabling HIV-1 gp120-dependent entry of COC genome. Fig. 
4 B shows entry of COC(HIV) pseudotypes in hCD4-, m6-, 
and m2-expressing HeLa cells. The results confirm the PCR 
data, with HeLa hCD4 being more susceptible  than HeLa 
m6, which in turn are more susceptible than HeLa m2. A few 
Discussion 
Taken together, these results show that m6 is a functional 
receptor for HIV-1 although the efficiency with which cell- 
free virus infects HeLa m6 is between 3- and 10-fold lower 
than that with which it infects HeLa hCD4 cells. This re- 
duced efficiency at the initial stage of infection is probably 
sufficient  to account for the slight delay in replication ki- 
netics (see Fig. 2). Our results also suggest that syncytium 
formation depends only on high affinity binding of CD4 to 
gpl20 and not, as has previously been proposed (16, 17, 19), 
on the sequence  of the CDR3-like loop (residues  86-89), 
which is substantially different between hCD4 (VEDQ) and 
rCD4 (LENK). In agreement with our results, a recent study 
in which hCD4 residues 81-92 were replaced by those of chim- 
panzee, rhesus, or mouse CD4, and residues 79-92 were com- 
prehensively mutated, no mutants were found in which syn- 
cytium formation was affected without gross changes in the 
structure of the molecule (37). Similarly, cells expressing chim- 
panzee  CD4  are  able  to  form  syncytia with  HIV-1  Env- 
expressing cells as efficiently  as those expressing hCD4 (37a, 
and Quentin Sattentau, personal communication). Recent 
work shows that the CDR3-derived peptides that inhibit syn- 
cytium formation are not specific since they also interfere with 
HTLV-I entry and noncompetitively inhibit the binding of 
both gp120  and a CDR2-directed mAb to CD4  (38). 
The reduction in infectability of HeLa m6 compared with 
HeLa hCD4 (3-10-fold) is proportionally greater than might 
be expected from the twofold reduction in monomeric affinity. 
The interaction between CD4 and gp120 on the viral surface 
may be multimeric (18, 39, 40).  If this were the case, the 
consequent decrease in avidity of m6 for gp120 could account 
for the greater than expected drop of infectability. To test 
this possibility, a comparison is needed between the predicted 
and actual levels of viral entry using other mutants whose 
affinities and on and off  rates of binding to gp120 are known. 
The present data suggest that the 70-fold reduction in affinity 
of m2 for gp120 results in a substantial decrease in both in- 
fectability and syncytium-forming  potential leading to abor- 
tive infection of HeLa m2 cultures. 
In summary, the results presented here strongly suggest 
that the presence of an effective gp120 binding site is all that 
is required for efficient HIV-1 receptor function of CD4 both 
in the formation of syncytia and the infection of  cells  by virions. 
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